The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Morning All, for all of you who could go, was there much talk about future funding? It is not like days of old where we would raise 6/8m a time and without a ball park figure for our mab deal it is harder to work out how it would be structured.
I am pretty sure for Redmile and Vulpes this was a major consideration for the first round. All thoughts welcome
Evening All,, and again thank you botski, will look forward to hearing that.
For all the plaudits, another 200k black trade at 17.75 presumably Calculas has gone through. I remember when they sold a fair few at 32p, and now another 13 odd million including THE 8 Million rnsEd. Would love to know who they are replacing our invest with?
Again thanks to all
GF, yes Botski posted he was going, which I take he will do his best to tape it as a few times before. Disappointed I cannot go it is only some 10 miles from home but as Mostan mobility problems make it impossible.
Sure you will all make the most of it and look forward to hearing each persons take.
Sorry to hear that LL wishing you a quick recovery. Unfortunately I am too dependant on my wheelchair and reading the posts from Kashdog and Ivyspivey myself and others have chosen to miss the event, it will IMHO be a very interesting event, shame to hear such threatening posts. Empty vessels indeed
Hi, chester, ot so much a queston at the AGM but in my 07.55 post you can understand my comments clearer, and as far as Zakari is concerned I would be very interested in their reply.
Come this time next year dependant on a few permutations funding will be very much on the agenda again, it would sure be useful to know the upfront payment and milestone payments with Genmab and another subsequent deal with the mabs. For sure Redmile would have had a plan from day one and I would love to hear there thoughts n the progress we are making so far. Bar getting back to optimising trials and patients I am pretty sure Redmile have a plan, I would just love to ow what it is!!
Hi Ruck, I still believe with Redmile, in particular, Vulpes and specialist legal advisers, we have that commercial expertise in place already, and further we have lined up investors and maybe Pharmas to take us forward. Probably why CH moved on and there has certainly been no rush to replace him.
TF, another u-turn? Last week you said you didn"t think there was any further news to come in response to Rats and a few of us, now you are suggesting Wednesday is a good day fr RNSs!!! Anything changed?
Chester, another very good post, 77 didn"t surprise me and Fasedawns 100 was not so far out. One of the reasons it was high was the aount of RNSs in a short time and the very high volume of trades (about 14 millio Interest remained high as the SP failed to hold initial rises) on the Genmab deal and all other items of news IMHO.
Have we noticed again the high number of 100k black trades at 18.75 which IMHO could well be CALCULAS still selling which puts into perspective the amount of trades and the regular small blue days we are seeing. We still have no idea as to how many they are prepared to sell and any halt in selling coupled with further good news would see some nice gains through the 20s. before the end of this year 2022. So just 6/7 weeks now to the end of the year it should certainly be a busy AGM and I hope the time allocated to questions will do us justice not just in quality but in what they can reasonably expected to be able to answer.
So much scope for a great AGM, and we are really not so far away from the highs of 27/28p reached just 18 months ago.
Exciting times guys and for sure anther excitig year 2023 to come ATB
Well just 6 full trading days until the AGM and I have been delighted to see us hitting timelines all over the platforms.
I know I am not alone in thinking we have another very good RNS to come before the AGM, certainly before the end of this year...................
On the 29th March we released an RNS re Covidity which I think is what the RNS will be about. In that Lindy said............
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "With this amendment to the COVIDITY trial allowing us to expand the patient population to reflect a real-world setting, we believe we will be better able to capture meaningful safety and immunogenicity data. Additionally we anticipate this will accelerate recruitment of volunteers in our COVIDITY Phase 1 clinical trial, and look forward to announcing data later in 2022."
Just perhaps that will launch us back into the 20s where many of us feel we should be.